Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.48 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423484 | 1.00 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL25970777 | 1.00 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL25971819 | 0.97 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL586123 | 0.97 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL25342396 | 0.95 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL28133679 | 0.90 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL18353935 | 0.84 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL14201896 | 0.83 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL21163962 | 0.82 | SMN1; SMN2 (0.58) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL19414808 | 0.82 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173024-B2 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2007-02-06 | — | — | US | disclosed |
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2005-01-27 | — | — | US | disclosed |
| EP-1401810-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003004468-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | DNPEP, PREP, ANPEP | HSD17B10 1513/4885SMN1; SMN2 2511/4885NPC1 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.